India’s government has not put in any pre-orders for the Pfizer and Moderna vaccines that were first to report encouraging Phase 3 trial results. But, alongside the US, India has the largest order of any country for the Oxford/AstraZeneca vaccine. This vaccine is already being produced in India, by the Serum Institute, ready for it to receive government approval. And it should be easier to distribute than some other vaccine candidates since it doesn’t need to get kept extremely cold. The latest good news on the efficacy of the Oxford vaccine is therefore the most encouraging sign yet that India has a route to ending its COVID-19 epidemic and the social distancing that continues to weigh on the economy.
Become a client to read more
This is premium content that requires an active Capital Economics subscription to view.
Already have an account?
You may already have access to this premium content as part of a paid subscription.
Sign in to read the content in full or get details of how you can access it
Register for free
Sign up for a free account to:
- Unlock additional content
- Register for Capital Economics events
- Receive email updates and economist-curated newsletters
- Request a free trial of our services